Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Utilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other Diseases.
Kallikrein-related peptidase 6 exacerbates disease in an autoimmune model of multiple sclerosis.
[Expression of chemokine like factor-like myelin and lymphocyte and related proteins for vesicle trafficking and membrane link transmembrane domain-containing protein 2 in rats with varicocele].
Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness.
The proteome of normal human retrobulbar optic nerve and sclera.
The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates.
ERK1/2 Activation in Preexisting Oligodendrocytes of Adult Mice Drives New Myelin Synthesis and Enhanced CNS Function.
Reducing the economic burden in management of Guillain-Barre syndrome using modified plasmapheresis.
Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS).
Differential Impact of Multiple Sclerosis on Cortical and Deep Gray Matter Structures in African Americans and Caucasian Americans.
Constipation prevalence in multiple sclerosis about a cohort of 81 patients.
Recombinant Antibody Fragments For Neurodegenerative Diseases.
Progression of alpha-synuclein pathology in multiple system atrophy of the cerebellar type.
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Effect of recombinant Lactococcus lactis producing myelin peptides on neuroimmunological changes in rats with experimental allergic encephalomyelitis.
Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.
Bilateral abducens nerve palsy in an infant case of fulminant acute disseminated encephalomyelitis: a case report.
The Transition to Secondary Progressive Multiple Sclerosis: An Exploratory Qualitative Study of Health Professionals' Experiences.
Clinical characteristics of disabling attacks at onset in patients with neuromyelitis optica spectrum disorder.
Drinking away fatigue in multiple sclerosis.
Autologous hematopoietic cell transplantation in multiple sclerosis.
Aquaporin 4 Antibody in the Korean Patient with New-Onset Optic Neuritis.
Brain activation changes during locomotion in middle-aged to older adults with multiple sclerosis.
The effects of fatigue, depression and the level of disability on the health-related quality of life of glatiramer acetate-treated relapsing-remitting patients with multiple sclerosis in Hungary.
Patient Management Problem.
Pages
« first
‹ previous
…
810
811
812
813
814
815
816
817
818
…
next ›
last »